RA Capital Management

RA Capital Management is a Boston-based investment advisor founded in 2004, specializing in the life sciences and healthcare sectors. The firm focuses on early-stage companies developing innovative technologies, products, and services in drug development, medical devices, diagnostics, and research tools. With a team of professionals trained in biology, chemistry, and medicine, RA Capital Management leverages its extensive industry and business development experience to identify and invest in promising healthcare ventures. As a Registered Investment Adviser, the firm employs a strategic approach that includes both venture capital investments and a hedge fund strategy, targeting opportunities primarily in the United States and Europe.

Daniel Bahcheli

Director, Research

Peter Balogh

Analyst

Ryan Berry

Associate

Theresa Cameron

Principal, Strategic Finance

Tess Cameron

Principal

Cristina Ghenoiu

Principal

Michael Gillespie MD

Investment Director

Reza Halse

President

Sonia Kartha Ph.D

Ventures Associate

Peter Kolchinsky

Managing Partner

Anurag Kondapalli

Principal

Andrew Levin

Partner and Managing Director

Dan Marks

Venture Principal

Kathryn Meng

Investment Director

David Migl Ph.D

Analyst, Investments

Emily Minkow

Executive Investment Director

Fuad Naser Ph.D

Analyst

Brigid O'Brien

Managing Partner

Josh Resnick

Senior Managing Director

Prithviraj Roy

Analyst

Zachary Scheiner Ph.D

Principal

Zach Scheiner

Principal

Rajeev Shah

Managing Partner

Rebecca Silberman Ph.D

Investment Director

Monica Stanciu Ph.D

Director

Laura Stoppel

Principal

Shan Shan Wang Ph.D

Associate Director

Past deals in Copenhagen

Hemab

Series B in 2023
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Hemab

Series A in 2021
Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.